Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21677213 | 0.78 | NLRP3 (0.40) | GAA | |
| SCHEMBL25771162 | 0.77 | HSD17B10 (0.37) | GAA | |
| SCHEMBL21677371 | 0.75 | NLRP3 (0.32) | — | |
| SCHEMBL23976181 | 0.69 | ADORA1 (0.38) | GAA | |
| SCHEMBL25633260 | 0.66 | PIK3R1 (0.39) | GAA | |
| SCHEMBL23952552 | 0.61 | PIK3R1 (0.33) | GAA | |
| SCHEMBL23952550 | 0.61 | KDM4E (0.31) | GAA | |
| SCHEMBL27075341 | 0.60 | PARP1 (0.41) | — | |
| SCHEMBL21677206 | 0.59 | NLRP3 (0.39) | GAA | |
| SCHEMBL23952163 | 0.59 | PDE4B (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230203064-A1 | TRICYCLIC COMPOUNDS AS INHIBITORS OF NLRP3 | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-29 | — | — | US | disclosed |
| US-20230203064-A1 | TRICYCLIC COMPOUNDS AS INHIBITORS OF NLRP3 | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-29 | — | — | US | disclosed |
| US-20230203064-A1 | TRICYCLIC COMPOUNDS AS INHIBITORS OF NLRP3 | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-29 | — | — | US | disclosed |
| EP-4139312-A1 | TRICYCLIC COMPOUNDS AS INHIBITORS OF NLRP3 | JANSSEN Pharmaceutica NV (BE) | 2023-03-01 | — | — | EP | disclosed |
| CN-115461345-A | Tricyclic compounds as NLRP3 inhibitors | 詹森药业有限公司 | 2022-12-09 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203064-A1 | TRICYCLIC COMPOUNDS AS INHIBITORS OF NLRP3 | NLRP3, NLRP1, NOD1 | GAA 3974/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.